Scholar Rock Holding Corporation (NASDAQ:SRRK) Given Consensus Rating of “Buy” by Brokerages

Scholar Rock Holding Corporation (NASDAQ:SRRK) has received a consensus rating of “Buy” from the fourteen analysts that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, ten have assigned a buy recommendation and three have given a strong buy recommendation to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $46.40.

Several equities analysts recently commented on SRRK shares. Barclays decreased their price objective on shares of Scholar Rock from $45.00 to $44.00 and set an “overweight” rating for the company in a research report on Wednesday, September 24th. HC Wainwright reduced their price target on shares of Scholar Rock from $50.00 to $44.00 and set a “buy” rating for the company in a research report on Tuesday, September 23rd. Leerink Partnrs raised shares of Scholar Rock to a “strong-buy” rating in a research report on Monday, September 15th. Piper Sandler reduced their price target on shares of Scholar Rock from $52.00 to $51.00 and set an “overweight” rating for the company in a research report on Wednesday, September 24th. Finally, Wedbush reissued an “outperform” rating and set a $50.00 price target on shares of Scholar Rock in a research report on Wednesday, June 18th.

Insider Transactions at Scholar Rock

In other news, Director Jeffrey S. Flier sold 11,136 shares of the firm’s stock in a transaction that occurred on Wednesday, July 16th. The shares were sold at an average price of $40.02, for a total transaction of $445,662.72. Following the sale, the director owned 24,070 shares of the company’s stock, valued at $963,281.40. This trade represents a 31.63% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Mo Qatanani sold 3,353 shares of the firm’s stock in a transaction that occurred on Monday, September 22nd. The stock was sold at an average price of $30.67, for a total transaction of $102,836.51. Following the sale, the insider directly owned 108,964 shares in the company, valued at $3,341,925.88. The trade was a 2.99% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 42,739 shares of company stock valued at $1,516,584 in the last 90 days. 13.30% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Scholar Rock

Institutional investors have recently added to or reduced their stakes in the stock. CWM LLC grew its stake in Scholar Rock by 152.8% in the 1st quarter. CWM LLC now owns 996 shares of the company’s stock valued at $32,000 after acquiring an additional 602 shares during the period. Federated Hermes Inc. acquired a new stake in Scholar Rock during the 1st quarter worth $71,000. GF Fund Management CO. LTD. boosted its stake in Scholar Rock by 21.9% during the 1st quarter. GF Fund Management CO. LTD. now owns 2,396 shares of the company’s stock worth $77,000 after purchasing an additional 430 shares during the last quarter. Strs Ohio acquired a new stake in Scholar Rock during the 1st quarter worth $77,000. Finally, Elevation Point Wealth Partners LLC acquired a new stake in Scholar Rock during the 2nd quarter worth $94,000. Institutional investors and hedge funds own 91.08% of the company’s stock.

Scholar Rock Stock Performance

SRRK stock opened at $37.47 on Monday. The firm has a market cap of $3.60 billion, a price-to-earnings ratio of -12.88 and a beta of 0.42. The company has a debt-to-equity ratio of 0.21, a quick ratio of 6.33 and a current ratio of 6.33. The firm has a 50-day simple moving average of $33.80 and a two-hundred day simple moving average of $33.14. Scholar Rock has a one year low of $7.11 and a one year high of $46.98.

Scholar Rock (NASDAQ:SRRK) last announced its quarterly earnings data on Wednesday, August 6th. The company reported ($0.98) EPS for the quarter, missing the consensus estimate of ($0.66) by ($0.32). During the same quarter in the previous year, the firm earned ($0.60) EPS. On average, equities analysts forecast that Scholar Rock will post -2.42 EPS for the current fiscal year.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.